Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 7:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children

NCT01545375
Conditions
Infections, Streptococcal
Interventions
Pneumococcal vaccine GSK2189242A, Placebo, Prevnar 13®, PedvaxHIB®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,806 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
5
States / cities
Chinle, Arizona • Fort Defiance, Arizona • Whiteriver, Arizona + 2 more
Completed Phase 4 Interventional Results available

Pneumococcal Vaccines in Patients With Asthma

NCT03260790
Conditions
Asthma
Interventions
PCV13, PPSV23
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
19 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Early Phase 1 Interventional Accepts healthy volunteers

Immune Response to Pneumococcal Vaccination in HIV Infected Individuals

NCT02515240
Conditions
Pneumococcal Infection
Interventions
PPV23
Biological
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
19 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Toledo, Ohio
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines

NCT03104075
Conditions
Pneumonia, Aging
Interventions
Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein, Pneumococcal Vaccine Polyvalent
Biological
Lead sponsor
The Jackson Laboratory
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Farmington, Connecticut
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab, methotrexate, 23-Valent Pneumococcal Polysaccharide Vaccine, Tetanus Toxoid Adsorbed Vaccine
Biological · Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
47
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 42 more
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

An Open Label Study of IgG Fc Glycan Composition in Human Immunity

NCT01967238
Conditions
Healthy
Interventions
IM Pneumococcal, meningococcal, or flu vaccine
Biological
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 80 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine, ActHIB, Pediarix, Prevnar, Menomune
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 15 Months
Enrollment
756 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
27
States / cities
Little Rock, Arkansas • Fountain Valley, California • Centennial, Colorado + 19 more
Conditions
Pneumococcal Disease
Interventions
13vPnC, PPSV23, 20vPnC
Biological
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
875 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
34
States / cities
Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 26 more
Conditions
Haemophilus Influenzae Type b
Interventions
GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108), ActHIB™, Pentacel™, Pediarix™, Prevnar 13™, Rotarix™, Engerix™-B, Infanrix™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
4,003 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
63
States / cities
Dothan, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 59 more
Conditions
Pneumococcal Infections
Interventions
13-valent pneumococcal conjugate vaccine (13vPnC), 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
2,141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
26
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 19 more
Conditions
Meningitis, Meningococcal Infection
Interventions
Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined), M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live, Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Rotavirus Vaccine, Hepatitis B Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 365 Days
Enrollment
580 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
25
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Jonesboro, Arkansas + 20 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants

NCT02543918
Conditions
Healthy
Interventions
Ixekizumab, Boostrix®, Pneumovax®23
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
3
States / cities
Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas
Conditions
High Risk for Serious Influenza, High Risk for Pneumonia
Interventions
Influenza vaccination, Pneumococcal polysaccharide vaccination
Biological
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Baton Rouge, Louisiana
Conditions
Pneumococcal Infections
Interventions
Tetanus-diphtheria toxoids (Td), 7-valent pneumococcal conjugate vaccine, 23-valent polysaccharide vaccine
Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
50 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Type 1 Diabetes
Interventions
Pneumovax 23- pneumococcal polysaccharide, Blood draw
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
3 Years to 18 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use, Corona Virus Infection, Blood Clot, Thrombocytopenia, Neuritis, Vasculitis, Influenza, Guillain-Barré, GWAS, Genetic Sequencing
Interventions
vaccinated
Biological
Lead sponsor
Neuroganics LLC
Industry
Eligibility
5 Years to 99 Years
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Northglenn, Colorado
Not listed Not applicable Interventional Accepts healthy volunteers

Pneumococcal Post-Vaccination Titers

NCT02726347
Conditions
Smokers, Elderly, Asthma, COPD, Recurrent Infections
Interventions
PPV-23
Biological
Lead sponsor
National Jewish Health
Other
Eligibility
19 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™, PNEUMOVAX™23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Orlando, Florida • West Palm Beach, Florida • Houston, Texas
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
dimethyl fumarate, tetanus diphtheria toxoids vaccine, 23-valent pneumococcal polysaccharide vaccine, meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent), non-pegylated interferon
Drug · Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Gilbert, Arizona • Thornton, Colorado • Fort Lauderdale, Florida + 11 more
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Pneumococcal Conjugate Vaccine in Aging Renal Transplant

NCT03802994
Conditions
Renal Transplantation, Aging
Interventions
23 valent pneumococcal polysaccharide vaccine, 13 valent conjugated pneumococcal vaccine, Peripheral blood sample
Drug · Biological · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
35 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Charleston, South Carolina
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
42 Days to 90 Days
Enrollment
2,409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
22
States / cities
Downey, California • Huntington Beach, California • San Diego, California + 18 more
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Meningococcal Polysaccharide Diphtheria Conjugate Vaccine, Measles, Mumps, Rubella and Varicella
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 12 Months
Enrollment
1,664 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
87
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 74 more
Conditions
HIV Infections
Interventions
Pneumococcal 7-valent conjugate vaccine, Pneumococcal polysaccharide vaccine, Hepatitis B vaccine, Measles, mumps, and rubella virus vaccine, live
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 23 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
24
States / cities
Birmingham, Alabama • Alhambra, California • Long Beach, California + 17 more
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV (GSK3389245A) lower dose formulation vaccine, RSV (GSK3389245A) higher dose formulation vaccine, GSK's multicomponent meningococcal B vaccine, Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine, GSK's pneumococcal polysaccharide conjugate vaccine, GSK's meningococcal group A, C, W-135 and Y conjugate vaccine, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 7 Months
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
4
States / cities
Atlanta, Georgia • Nampa, Idaho • Louisville, Kentucky + 1 more